JP2018522891A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522891A5
JP2018522891A5 JP2018503215A JP2018503215A JP2018522891A5 JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5 JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5
Authority
JP
Japan
Prior art keywords
brain injury
traumatic brain
pharmaceutical composition
peptides
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018503215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/054318 external-priority patent/WO2017013599A1/en
Publication of JP2018522891A publication Critical patent/JP2018522891A/ja
Publication of JP2018522891A5 publication Critical patent/JP2018522891A5/ja
Priority to JP2022079211A priority Critical patent/JP2022113682A/ja
Pending legal-status Critical Current

Links

JP2018503215A 2015-07-21 2016-07-20 凝集ペプチドを標的とする外傷性脳損傷の治療方法 Pending JP2018522891A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079211A JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195183P 2015-07-21 2015-07-21
US62/195,183 2015-07-21
US201662288813P 2016-01-29 2016-01-29
US62/288,813 2016-01-29
PCT/IB2016/054318 WO2017013599A1 (en) 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079211A Division JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Publications (2)

Publication Number Publication Date
JP2018522891A JP2018522891A (ja) 2018-08-16
JP2018522891A5 true JP2018522891A5 (cg-RX-API-DMAC10.html) 2019-08-15

Family

ID=56550266

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018503215A Pending JP2018522891A (ja) 2015-07-21 2016-07-20 凝集ペプチドを標的とする外傷性脳損傷の治療方法
JP2022079211A Pending JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079211A Pending JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Country Status (7)

Country Link
US (1) US11327080B2 (cg-RX-API-DMAC10.html)
EP (1) EP3325506A1 (cg-RX-API-DMAC10.html)
JP (2) JP2018522891A (cg-RX-API-DMAC10.html)
CN (1) CN107849125A (cg-RX-API-DMAC10.html)
AU (1) AU2016295650A1 (cg-RX-API-DMAC10.html)
CA (1) CA2991856A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017013599A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1827493A4 (en) * 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
AU2011326564A1 (en) * 2010-11-10 2013-05-09 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US20150126390A1 (en) * 2013-09-12 2015-05-07 Washington University Multiplex avidity profiling of protein aggregates
CN106661103B (zh) * 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体

Similar Documents

Publication Publication Date Title
Baron et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy
JP2014530226A5 (cg-RX-API-DMAC10.html)
JP2017149726A5 (cg-RX-API-DMAC10.html)
Wang et al. Age-associated dopaminergic neuron loss and midbrain glia cell phenotypic polarization
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2016210372A3 (en) Methods to treat neurological diseases
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
Lee et al. Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
HRP20240817T1 (hr) Kombinirana terapija koja sadrži ivosidenib, citarabin i daunorubicin ili idarubicin za liječenje akutne mijelogene leukemije
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
JP2016507547A5 (cg-RX-API-DMAC10.html)
Alme et al. Fingolimod does not enhance cerebellar remyelination in the cuprizone model
Liu et al. Effects of autophagy on synaptic-plasticity-related protein expression in the hippocampus CA1 of a rat model of vascular dementia
Makino et al. Enhancement of immobility in mouse forced swimming test by treatment with human interferon
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
JP2009545526A5 (cg-RX-API-DMAC10.html)
EP3362096A4 (en) OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS
JP2019528285A5 (cg-RX-API-DMAC10.html)
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
EP3960858A4 (en) SMALL RNA DRUG USED TO PREVENT AND TREAT INFLAMMATION-RELATED DISEASES AND COMBINATIONS THEREOF
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
WO2023245156A3 (en) Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse